GlassScriptPhysician profile
Syed A Idris
NPI 1942317060
$1,278.21
in general payments reported to CMS, 2019-2025
23 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $46.42 · 2021: $58.26 · 2022: $200 · 2023: $390 · 2024: $163 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.00 | 2022-2025 | |
| Livanova USA, INC. | $174.51 | 2019-2021 | |
| Eisai INC. | $117.90 | 2023 | |
| Allergan, INC. | $67.06 | 2020-2021 | |
| Avion Pharmaceuticals | $39.45 | 2022-2023 | Dhivy |
| Sk Life Science, INC. | $37.44 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $34.91 | 2025 | Ultomiris |
| Axsome Therapeutics, INC. | $33.78 | 2025 | Symbravo |
| Banner Life Sciences, LLC | $33.58 | 2022-2023 | |
| Argenx US, INC. | $29.36 | 2025 | Vyvgart Hytrulo |
| Lilly USA, LLC | $28.36 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $24.90 | 2022 | |
| Mdd US Operations, LLC | $24.55 | 2023 | Gocovri |
| Tg Therapeutics, INC. | $22.79 | 2023 | |
| Ucb, INC. | $21.66 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.25 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.10 | 2023 | Rexulti |
| Neurelis, INC. | $14.31 | 2023 | Valtoco |
| Aprecia Pharmaceuticals, LLC | $14.17 | 2023 | Spritam |
| Horizon Therapeutics Plc | $14.03 | 2023 | Uplizna |
| Abbott Laboratories | $13.27 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Idris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.